Market Overview

Quest Diagnostics: What The Heck Is Happening?

Quest Diagnostics: What The Heck Is Happening?
Related DGX
Earnings Scheduled For January 26, 2017
Deutsche Bank Optimistic On Fundamentals In Life Science Tools/Diagnostics Sector

Quest Diagnostics Inc (NYSE: DGX) is up nearly 10 percent on Friday after unconfirmed market chatter suggested the company has hired Goldman Sachs to explore a sale.

Shares were halted on volatility at 10:34 a.m. ET, and since resuming, shares hit the $86 mark before trading down near $81.

Bloomberg reporter Tara Lachapelle tweeted "is this $dgx and $lh stuff just an avon sequel...," adding: "avon part 2?" in a separate post.

Lachapelle has since deleted the tweets.

Related Link: Valeant CEO: Healthcare Sector A 'Bit Of A Bubble'

According to RBC Analyst Frank G. Morgan, "DGX's spike is probably just a rumor, things like this happen all the time." In an interview with Benzinga, Morgan highlighted the litany of unsubstantiated rumors that take place in the healthcare space.

Quest Diagnostics declined to comment on the share price move.

As of this writing, Quest is up 9.2 percent on the day.


Latest Ratings for DGX

Mar 2017Bank of AmericaUpgradesUnderperformNeutral
Jan 2017Deutsche BankInitiates Coverage OnBuy
Jan 2017Deutsche BankInitiates Coverage OnBuy

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Short Ideas Rumors Exclusives Analyst Ratings Trading Ideas Best of Benzinga


Related Articles (DGX)

View Comments and Join the Discussion!